JAGX - Jaguar Health Inc Stock Price, Fair Value and News

0.23USD+0.02 (+9.52%)Delayed as of 30 Apr 2024, 12:35 pm ET

Market Summary

USD0.23+0.02

Delayedas of 30 Apr 2024, 12:35 pm

9.52%

JAGX Stock Price

View Fullscreen

JAGX RSI Chart

JAGX Valuation

Market Cap

4.8M

Price/Earnings (Trailing)

-0.12

Price/Sales (Trailing)

0.35

EV/EBITDA

0.05

Price/Free Cashflow

-0.15

JAGX Price/Sales (Trailing)

JAGX Profitability

Operating Margin

82.96%

EBT Margin

-350.46%

Return on Equity

-843.37%

Return on Assets

-81.36%

Free Cashflow Yield

-686.2%

JAGX Fundamentals

JAGX Revenue

Revenue (TTM)

12.0M

JAGX Earnings

Earnings (TTM)

-41.3M

Earnings Growth (Yr)

-7.6%

Earnings Growth (Qtr)

-17.9%

Breaking Down JAGX Revenue

52 Week Range

0.25

(Low)(High)

Last 7 days

16.7%

Last 30 days

133.3%

Last 90 days

90.9%

Trailing 12 Months

-58.0%

How does JAGX drawdown profile look like?

JAGX Financial Health

Current Ratio

Debt/Equity

2.2

Debt/Cashflow

-3.09

JAGX Investor Care

Shares Dilution (1Y)

1658.91%

Diluted EPS (TTM)

-2.28

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	6.2M	8.1M	10.1M	12.0M
2021	0	0	0	4.3M
2020	5.1M	6.5M	8.3M	9.4M
2019	5.2M	6.0M	5.9M	5.8M
2018	4.3M	4.3M	4.4M	4.4M
2017	925.8K	1.8M	2.8M	4.4M
2016	234.1K	195.1K	167.8K	141.5K
2015	0	0	0	258.4K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Jaguar Health Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2024	chaturvedi pravin r	acquired	-	-	134	chief scientific officer
Apr 05, 2024	wolin jonathan s.	acquired	-	-	89.00	chief of staff, cco & gc
Apr 05, 2024	lizak carol r.	acquired	-	-	60.00	chief financial officer
Apr 05, 2024	king steven r.	acquired	-	-	178	see remarks
Apr 05, 2024	conte lisa a	acquired	-	-	600	ceo and president
Aug 14, 2023	king steven r.	acquired	-	-	159,168	see remarks
Aug 14, 2023	conte lisa a	acquired	-	-	383,605	ceo and president
Aug 14, 2023	micek john	acquired	-	-	68,568	-
Aug 14, 2023	bochnowski james j	acquired	-	-	76,613	-
Aug 14, 2023	siegel jonathan b.	acquired	-	-	68,568	-

Which funds bought or sold JAGX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-20,887	29,120	-%
Feb 26, 2024	Virtu Financial LLC	added	342	9,000	15,000	-%
Feb 15, 2024	Farther Finance Advisors, LLC	sold off	-100	-1.00	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	2,507	2,507	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	unchanged	-	-81.00	113	-%
Feb 14, 2024	BOOTHBAY FUND MANAGEMENT, LLC	added	67.17	-205	7,536	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	new	-	9,425	9,425	-%
Feb 14, 2024	Royal Bank of Canada	added	52,100	-	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	29,270	29,270	-%
Feb 13, 2024	Csenge Advisory Group	added	210	5,234	11,734	-%

Are Funds Buying or Selling JAGX?

Are funds buying JAGX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own JAGX

No. of Funds

Unveiling Jaguar Health Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Dec 29, 2023	iliad research & trading, l.p.	9.6%	4,875,000	SC 13G
Jul 13, 2023	fife john m.	-	19,086	SC 13G
Feb 23, 2023	mailman joshua	1.4%	28,026	SC 13G/A
Feb 14, 2023	mailman joshua	6.5%	9,849,138	SC 13G/A
Aug 26, 2022	streeterville capital llc	9.75%	11,500,000	SC 13G
May 10, 2022	mailman joshua	11.1%	8,614,138	SC 13G
Jan 11, 2022	oasis capital, llc	9.99%	4,604,484	SC 13G
Feb 12, 2021	sagard capital partners, l.p.	2.8%	1,910,043	SC 13G/A
Feb 11, 2021	ionic ventures, llc	0%	0	SC 13G/A
Jan 25, 2021	oasis capital, llc	9.99%	6,874,665	SC 13G

Recent SEC filings of Jaguar Health Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	S-3	S-3
Apr 17, 2024	10-K/A	Annual Report
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 09, 2024	8-K	Current Report
Apr 02, 2024	424B5	Prospectus Filed
Apr 01, 2024	10-K	Annual Report

Peers (Alternatives to Jaguar Health Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

Jaguar Health Inc News

Latest updates

Jaguar Health Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1
Revenue	-	-	-	-	-	-	2,576,000	2,773,000	3,167,000	869,000	1,506,500	973,000	1,706,000	1,590,000	1,595,876	1,132,067	883,846	804,356	1,542,041	1,100,214	896,521	822,410
Cost Of Revenue	-19.2%	495,000	613,000	456,000	455,000	469,000	789,000	784,000	1,031,000	676,000	743,000	948,000	1,260,000	865,000	956,828	736,733	608,024	464,161	-	-	-	-
Costs and Expenses	-26.8%	9,546,000	13,046,000	9,400,000	14,379,000	12,907,000	7,743,000	8,148,000	11,618,000	8,523,000	7,330,500	7,700,000	12,328,000	7,365,000	-	7,638,279	7,962,920	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	7,364,841	13,706,297	7,638,279	7,962,920	5,932,617	22,223,157	8,440,303	3,246,774	4,698,012
S&GA Expenses	-17.1%	1,748,500	2,109,000	2,144,000	2,835,000	2,300,500	1,881,000	1,529,000	1,730,000	1,469,000	1,500,000	1,698,000	2,173,000	1,565,000	2,712,372	2,716,752	2,690,262	1,712,190	-	-	-	-
R&D Expenses	-27.4%	4,311,000	5,940,000	2,451,000	4,945,000	5,482,500	1,904,000	1,522,000	1,405,000	1,582,000	1,394,000	1,307,000	1,698,000	1,421,000	1,310,830	1,481,166	1,604,886	757,866	-	-	-	-
EBITDA Margin	29.7%	-2.84	-4.05	-5.03	-7.42	-9.79	-3.12	-3.34	-4.10	-4.47	-4.67	-4.60	-6.85	-8.52	-9.84	-7.18	-	-	-	-	-	-
Interest Expenses	7.9%	2,948,000	2,731,000	2,536,000	4,194,000	2,433,000	1,533,000	581,000	479,000	199,000	174,000	1,353,000	3,657,000	547,000	442,817	872,044	711,802	602,022	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	10,000	-	-	-	-	-	19,344	-990,549	-12,190,693	-	-
Earnings Before Taxes	34.7%	-8,232,000	-12,609,000	-9,390,000	-18,164,000	-14,318,000	-8,769,000	-7,866,000	-9,238,000	-7,936,000	-5,930,000	-7,545,000	-	-8,304,000	-12,653,885	-6,138,352	-	-	-21,198,007	-7,430,849	-	-
EBT Margin	25.3%	-4.05	-5.42	-6.64	-9.42	-12.13	-3.60	-3.72	-4.70	-5.88	-5.96	-5.91	-8.02	-9.28	-10.74	-8.06	-	-	-	-	-	-
Net Income	31.9%	-8,522,000	-12,520,000	-9,367,000	-17,986,000	-14,318,000	-8,769,000	-7,866,000	-9,238,000	-7,936,000	-5,959,000	-7,555,000	-16,721,000	-8,304,000	-12,653,885	-6,138,352	-7,657,183	-5,696,637	-	-	-	-
Net Income Margin	24.9%	-4.05	-5.39	-6.61	-9.39	-12.13	-3.60	-3.73	-4.71	-7.55	-6.67	-7.71	-7.27	-6.68	-7.28	-9.10	-	-	-	-	-	-
Free Cashflow	24.7%	-6,423,000	-8,532,000	-10,457,000	-7,695,000	-8,923,000	-4,061,000	-2,919,000	-4,002,000	-4,303,000	-3,140,000	-8,547,000	-5,305,000	-3,465,000	-4,902,078	-2,810,241	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	11.9%	51.00	45.00	52.00	57.00	47.00	51.00	50.00	53.00	53.00	59.00	70.00	69.00	43.00	36.00	38.00	33.00	36.00	36.00	36.00	41.00	41.00
Current Assets	26.8%	28.00	22.00	28.00	32.00	22.00	25.00	23.00	28.00	28.00	24.00	44.00	44.00	18.00	11.00	12.00	7.00	10.00	8.00	7.00	7.00	8.00
Cash Equivalents	100.5%	6.00	3.00	9.00	14.00	5.00	11.00	9.00	17.00	17.00	12.00	32.00	32.00	8.00	1.00	3.00	1.00	4.00	2.00	2.00	3.00	3.00
Inventory	9.7%	9.00	8.00	8.00	9.00	7.00	7.00	7.00	5.00	5.00	5.00	3.00	3.00	3.00	2.00	2.00	3.00	2.00	2.00	2.00	3.00	3.00
Net PPE	-2.9%	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	4.3%	46.00	44.00	46.00	49.00	49.00	48.00	47.00	45.00	41.00	38.00	38.00	37.00	26.00	28.00	25.00	17.00	16.00	15.00	29.00	25.00	27.00
Current Liabilities	12.3%	14.00	12.00	29.00	31.00	30.00	27.00	23.00	19.00	15.00	12.00	13.00	13.00	13.00	26.00	25.00	16.00	15.00	9.00	21.00	25.00	27.00
Shareholder's Equity	245.8%	5.00	1.00	6.00	8.00	-1.36	4.00	3.00	8.00	12.00	22.00	32.00	32.00	17.00	8.00	2.00	6.00	11.00	11.00	-	7.00	5.00
Retained Earnings	-3.0%	-308	-299	-291	-279	-266	-259	-246	-237	-219	-205	-192	-178	-166	-158	-150	-141	-133	-127	-119	-102	-94.55
Additional Paid-In Capital	4.2%	314	301	298	287	267	263	250	246	231	227	225	211	184	160	151	146	142	138	118	110	100
Shares Outstanding	11.2%	23.00	21.00	11.00	5.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	932.13*
Minority Interest	-214.3%	-0.06	0.00	0.00	0.00	-0.70	-0.05	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	10.00	-	-	-	25.00	-	-	-	216	-	-	-	15.00	-	-	-	8.00	-	-

Cashflow (Last 12 Months)

(In )

Cashflow (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-9.7%	-7,451,000	-6,790,000	-9,056,000	-9,945,000	-6,423,000	-8,529,000	-10,457,000	-7,695,000	-8,923,000	-9,432,000	-9,907,000	-6,708,000	-4,061,000	-2,919,000	-4,002,000	-4,296,000	-3,140,000	-8,547,000	-5,305,000	-3,465,000	-4,902,078
Share Based Compensation	9.3%	577,000	528,000	527,000	480,000	497,000	646,000	1,112,000	1,063,000	1,142,000	1,165,000	1,033,000	634,000	640,000	675,000	749,000	760,000	1,006,000	1,110,000	446,000	427,000	607,083
Cashflow From Investing	-	-	-	-	-	-361,000	-56,000	-	-	10,478,000	-10,478,000	-	-	-	-	-	-7,000	-	-	-	-	-
Cashflow From Financing	655.9%	10,650,000	1,409,000	3,357,000	18,811,000	1,638,000	10,147,000	3,246,000	8,150,000	3,121,000	373,000	9,575,000	30,868,000	10,802,000	1,253,000	5,414,000	2,023,000	4,953,000	9,003,000	4,347,000	3,469,000	6,744,140
Buy Backs	-	-	-	-	-	-	-	-	-	-	50.00	-	-	-	6.00	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

JAGX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Cost of product revenue	$ 2,037	$ 2,019
Research and development	18,596	17,647
Sales and marketing	6,460	8,837
General and administrative	16,588	17,868
Impairment loss on intangible asset	371
Total operating expenses	44,052	46,371
Loss from operations	(34,291)	(34,415)
Interest expense	(6,382)	(12,723)
Change in fair value of freestanding and hybrid financial instruments designated at Fair Value Option	(5,125)	(20)
Gain (loss) on extinguishment of debt	3,697	(2,187)
Other income	200	950
Loss before income tax	(41,901)	(48,395)
Income tax expense
Net loss	(41,901)	(48,395)
Net loss attributable to noncontrolling interest	(601)	(941)
Net loss attributable to common stockholders	$ (41,300)	$ (47,454)
Net loss per share, basic	$ (1.79)	$ (36.18)
Net loss per share, diluted	$ (1.79)	$ (36.18)
Weighted-average common stock outstanding, basic	23,068,423	1,311,519
Weighted-average common stock outstanding, diluted	23,068,423	1,311,519
Product revenue, net
Revenue
Revenue	$ 9,761	$ 11,956

JAGX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 6,469	$ 5,469
Accounts receivable, net	1,967	1,879
Other receivable	217	588
Inventory	9,189	7,024
Prepaid expenses and other current assets	10,121	7,361
Total current assets	27,963	22,321
Property and equipment, net	496	557
Operating lease - right-of-use asset	1,176	1,140
Intangible assets, net	20,116	22,439
Other assets	1,012	995
Total assets	50,763	47,452
Current liabilities:
Accounts payable	4,974	5,808
Accrued liabilities	3,798	8,165
Operating lease liability, current	348	483
Notes payable, current	4,867	15,883
Total current liabilities	13,987	30,339
Operating lease liability, net of current portion	886	725
Notes payable, net of discount, net of current portion (includes notes designated at Fair Value Option amounting to $31.0 million as of December 31, 2023 and $7.8 million December 31, 2022, respectively)	30,993	17,744
Total liabilities	45,866	48,808
Commitments and contingencies (See Note 5)
Stockholders' equity (deficit)
Additional paid-in capital	313,854	266,971
Noncontrolling interest	(64)	(699)
Accumulated deficit	(308,248)	(266,948)
Accumulated other comprehensive loss	(652)	(680)
Total stockholders' equity (deficit)	4,897	(1,356)
Total liabilities and stockholders' equity (deficit)	50,763	47,452
Series G convertible preferred stock
Stockholders' equity (deficit)
Preferred stock value
Series H convertible preferred stock
Stockholders' equity (deficit)
Preferred stock value
Series I convertible preferred stock
Stockholders' equity (deficit)
Preferred stock value
Common stock - voting
Stockholders' equity (deficit)
Common stock value	7
Common stock - non-voting
Stockholders' equity (deficit)
Common stock value

About Jaguar Health Inc

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.

CEO	Ms. Lisa A. Conte
WEBSITE	https://jaguar.health
INDUSTRY	Biotechnology
EMPLOYEES	60

Jaguar Health Inc Frequently Asked Questions

What is the ticker symbol for Jaguar Health Inc? What does JAGX stand for in stocks?

JAGX is the stock ticker symbol of Jaguar Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Jaguar Health Inc (JAGX)?

As of Mon Apr 29 2024, market cap of Jaguar Health Inc is 4.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of JAGX stock?

You can check JAGX's fair value in chart for subscribers.

What is the fair value of JAGX stock?

You can check JAGX's fair value in chart for subscribers. The fair value of Jaguar Health Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Jaguar Health Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for JAGX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Jaguar Health Inc a good stock to buy?

The fair value guage provides a quick view whether JAGX is over valued or under valued. Whether Jaguar Health Inc is cheap or expensive depends on the assumptions which impact Jaguar Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JAGX.

What is Jaguar Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, JAGX's PE ratio (Price to Earnings) is -0.12 and Price to Sales (PS) ratio is 0.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JAGX PE ratio will change depending on the future growth rate expectations of investors.